Welcome to YHEC’s publication hub

Our latest research, all in one place. Browse our collection of journal articles, reports and conference proceedings to see how we’re contributing to HEOR research. Remember to: 

  • Filter by service, therapeutic area, or geography to narrow your results.
  • Search directly for keywords or specific titles to find what you need instantly.
Peer-reviewed publication

The Economic and Clinical Impact of an AI-Assisted Tool for Colonoscopy to Support Diagnosis of Colorectal Cancer in Symptomatic Patients in England

YHEC authors: Luc Curtis-Gretton, Angel Varghese, Karina Watts, Hayden Holmes
Publication date: November 2026
Publishers: Springer Nature Link
Journal: BMC Digital Health

Abstract

BACKGROUND: Colorectal cancer (CRC) remains a leading cause of cancer-related mortality in the UK. Early detection and removal of adenomatous polyps are essential to improving outcomes. Artificial intelligence-assisted colonoscopy tools, such as GI Genius (GIG), may enhance adenoma detection rates (ADR) and reduce the likelihood of missed lesions.

METHODS: A patient-level simulation cost-effectiveness model was developed to estimate the economic and clinical impact of GIG-assisted colonoscopy compared with standard colonoscopy alone in a symptomatic for suspected CRC population in England. The model adopted a National Health Service and Personal Social Services perspective, with a lifetime time horizon. Key model inputs were informed by the NAIAD trial, which evaluated the impact of GIG-assisted colonoscopy on ADR, compared with standard colonoscopy. Base case and probabilistic sensitivity analysis (PSA) were conducted to estimate the incremental cost-effectiveness ratio and the probability of cost effectiveness.

RESULTS: Base case results suggest that GIG is a cost-effective intervention, associated with per-person cost savings of £69 and quality-adjusted life year (QALY) gains of 0.046. This was primarily due to increased ADR and subsequent reduced CRC incidence. Scenario analyses testing uncertainty around the sensitivity of colonoscopy, clinical outcomes for those initially undiagnosed, differences in outcomes across experienced and non-experienced endoscopists, and the total costs of GIG produced findings that were consistent with the base case and did not materially change the estimated costs or QALYs. PSA results indicate that GIG is cost effective in 53% of simulations at the £20,000 per QALY gained threshold. This uncertainty is attributable to the marginal change in QALY outcomes between arms of the model, meaning that minor fluctuations in QALY outcomes between PSA iterations lead to large variations in the ICER.

CONCLUSIONS: The results highlight that GIG is a cost-saving intervention that can improve health outcomes by increasing ADRs. Scenario analyses broadly support the base case findings, suggesting that the conclusions were generally consistent across the alternative assumptions explored. PSA results highlighted considerable decision uncertainty, driven by the small incremental differences in QALYs. PSA results highlight considerable decision uncertainty, driven by the small incremental differences in QALYs.

Peer-reviewed publication

Cost-Effectiveness of Transcatheter Aortic Valve Implantation for Asymptomatic Severe Aortic Stenosis in the Kingdom of Saudi Arabia

YHEC authors: Madison Montgomery, Heather Davies, Lucy Hillcoat
Publication date: October 2026
Journal: Frontiers in Cardiovascular Medicine

Abstract

INTRODUCTION: Aortic stenosis (AS) is defined as the narrowing of the aortic valve. The benefits of implementing early aortic valve replacement (AVR), while the AS is asymptomatic, have been demonstrated in various clinical trials compared with clinical surveillance (CS) of delayed AVR upon symptom onset. The study aims to estimate the cost-effectiveness of transcatheter aortic valve implantation (TAVI) for the treatment of asymptomatic severe aortic stenosis (aSAS) in the Kingdom of Saudi Arabia (KSA).
METHODS: A cost–utility analysis compared TAVI using the SAPIEN 3/SAPIEN 3 Ultra valve with CS in an aSAS population. A Markov model consisting of three health states—alive and well, stroke, and death—captured the peri-procedural and long-term outcomes across a lifetime horizon. Inputs were derived from the EARLY TAVR trial (NCT03042104) and existing literature.
RESULTS: The model findings estimated that TAVI was cost-saving and more effective (dominant) compared with CS for people with aSAS, with a 97.3% probability of being cost-effective. Incremental results per person included an estimated cost saving of SAR 33,414, an estimated quality-adjusted life year gain of 0.17, and an estimated life-year gain of 0.12. The key driver of the model was the weighting of disabling stroke for the CS arm.
CONCLUSION: Early implementation of TAVI for those with aSAS is estimated to result in reduced costs and greater benefits compared with CS. These findings support the idea that timely intervention could enhance AS disease management in line with KSA policy.

Peer-reviewed publication

What is the Role of Multidisciplinary Methods to Support Environmental Sustainability in Health Technology Assessment?

YHEC authors: Melissa Pegg, Emma Bishop, Karina Watts
Publication date: October 2026
Publishers: HTAi
Journal: International Journal of Technology Assessment in Healthcare

Abstract

Healthcare contributes up to 8.5 percent of global carbon emissions, amongst other environmental impacts including intensive water consumption, plastics in our environment and pharmaceutical associated pollution. Healthcare supply chains are the largest contributor of environmental impact, accounting for up to 80 percent of total health sector emissions. Health technology assessment (HTA) can help support the mitigation of this impact by integrating sustainability considerations into policy making. Current literature indicates emission values are being included in some procurement decisions, and some HTA agencies are collecting environmental data or developing environmental domains in their strategies. However, there are no HTA agencies globally that officially include environmental outcomes as part of the decision-making framework. Adapting HTA to include environmental impacts will require integrating multidisciplinary approaches to make decisions that promote environmental sustainability. A scoping review was undertaken to identify such multidisciplinary methods. Multiple databases and gray literature sources were searched to identify relevant studies. The identified methods were appraised based on predefined criteria for HTA suitability, focusing on comprehensiveness, feasibility, and transparency. Key methods and frameworks identified include environmental life cycle assessment, cost–benefit analysis, and discrete choice experiments. Frameworks were ranked based on their potential suitability for implementing environmental impacts into HTA. Approaches such as One Health and circular economy provide possible foundations for environmental sustainability frameworks in HTA. Combining assessment methods to support trade-off considerations may strengthen decision making, although further research should examine stakeholder perspectives and implementation barriers.

Peer-reviewed publication

Economic Evaluation of Community-Based Lipid Testing to Improve Primary and Secondary Prevention of Cardiovascular Disease

YHEC authors: Barbara Uzdzinska, Nick Hex, Rachael MacDonald
Publication date: October 2026
Journal: BMC Health Services Research

Abstract

BACKGROUND: The NHS Health Check is designed to identify individuals at high risk of preventive diseases such as cardiovascular disease (CVD) – but uptake remains low. This study aims to evaluate the one-year incremental cost and lifetime cost effectiveness of community-based lipid testing (PocDoc Health Heart Check) compared with the NHS Health Check or primary care medication reviews.

METHODS: An early economic model was developed, which evaluated PocDoc testing in five settings: the workplace, community, pharmacy, at-home via-pharmacy invitation and case-finding from the CVD register. Deterministic sensitivity analysis was used to evaluate uncertainty, and a threshold of £20,000 per quality-adjusted life year (QALY) was used for the incremental cost-effectiveness ratio (ICER).

RESULTS: PocDoc’s per-person test cost is lower than the NHS Health Check. However, its higher uptake leads to higher short-term costs. In the short term, the incremental cost compared with standard of care ranges from £6.08 to £36.66 per person. In the long term, PocDoc is a cost-effective use of resources in all test settings: the ICER ranges from £1,915 to £7,884 per QALY. The long-term results are sensitive to changes in lifetime costs and QALYs.

CONCLUSIONS: Community-based lipid testing using PocDoc Healthy Heart Checks in pharmacies, workplaces and the community could be a cost-effective intervention to identify individuals at high risk of CVD compared with the NHS Health Check. PocDoc testing could also be a cost-effective alternative to medication reviews for people on the UK CVD register who are non-adherent.

Peer-reviewed publication

Beyond Carbon Footprints: Four Methodological Extensions for Environmental Sustainability Assessment in Health Technology Assessment

YHEC authors: Matthew Taylor
Publication date: October 2026
Journal: Global Health Economics and Sustainability

Abstract

When environmental outcomes are included in health economic analyses, many studies tend to focus only on the direct carbon footprint of the technologies being assessed. However, this narrow approach ignores several highly important factors. This article is intended to be an opening proposition rather than claiming to have fully formed answers. It proposes four additions to the environmental evaluation of healthcare interventions. The first is to include all downstream impacts. The second is to account for the environmental impact of displaced healthcare funding. The third is to account for the environmental impact of changes in life expectancy. Finally, the fourth recommendation is to use a decision rule to compare trade-offs between health gains (or losses) and environmental harm (or benefit). A hypothetical case study is used to illustrate how each of these recommendations can change the results of an evaluation. It is demonstrated that, whilst the narrow approach implied that a new technology might reduce environmental harm (a 5 kg reduction in CO2 equivalent emissions), the wider considerations demonstrate that the impact may be far larger (an increase of 19,119 kg CO2 equivalent emissions). Although the case study is hypothetical, the principles demonstrate that ignoring the wider impacts of health policies may miss important consequences.

Peer-reviewed publication

Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: Economic Evaluation using Randomised Controlled Trial Data

YHEC authors: Joe Moss
Publication date: October 2026
Journal: Addiction

Abstract

BACKGROUND AND AIMS: Long-term strong opioid use for chronic non-malignant pain (CNMP) represents a significant public health challenge, associated with reduced health-related quality of life (HRQoL) and increased mortality. The Improving the Wellbeing of people with Opioid Treated CHronic pain (I-WOTCH) trial demonstrated that a multicomponent intervention supporting opioid withdrawal in people with CNMP successfully reduced opioid consumption compared with best usual care (BUC), without adversely affecting perceived pain levels. This study aimed to assess the value-for-money of the strategies tested in the I-WOTCH trial, from the perspective of the United Kingdom National Health Service (NHS) and Personal and Social Services.

DESIGN, SETTING AND PARTICIPANTS: Within-trial cost-consequence (CCA) and model-based cost-effectiveness analyses (CEA), over one year and lifetime horizons, respectively. Data were sourced from the I-WOTCH trial, which recruited 608 participants from 191 primary care centres in England between May 2017 and January 2019 and followed them up for up to 12 months. Participants received either BUC or 3 group sessions (lasting one day each) led by a trained intervention nurse and by a lay person with CNMP and lived experience with opioid tapering. These sessions, designed to develop self-management skills, were supplemented by ongoing one-to-one support from nursing and lay personnel during follow-up. We used a probabilistic state-transition model to predict expected quality-adjusted life years (QALYs) and costs (in UK £) of each strategy over the lifetime of an individual. Model input parameters were derived mostly from the I-WOTCH trial. Opioid-related excess mortality and fracture rates were extracted from the literature.

MEASUREMENTS: Individual-level healthcare resource use and generic HRQoL [measured using the EuroQOL five dimensions questionnaire (Equation 5D)] were collected at baseline, 4, 8 and 12 months, and analysed to estimate total costs and health consequences for the I-WOTCH and BUC groups.

FINDINGS: I-WOTCH had higher costs and similar HRQoL outcomes compared with BUC at 12 months. When accounting for long-term reductions in mortality and morbidity from decreased exposure to strong opioids, our long-term model predicted I-WOTCH to yield higher costs and higher QALYs than BUC over the patient's lifetime, resulting in a base case incremental cost-effectiveness ratio of £29 543/QALY (2019 prices). Results were sensitive to structural assumptions in the model (i.e. cohort starting age, treatment effect weaning rate). Our probabilistic sensitivity analysis found I-WOTCH to have a 50% probability of being cost-effective compared with BUC for willingness-to-pay thresholds ranging between 0 and £100 000/QALY.

CONCLUSIONS: The Improving the Wellbeing of people with Opioid Treated CHronic pain intervention supporting opioid withdrawal in people with chronic non-malignant pain appears to be cost-effective on average, but further research is warranted to reduce current levels of decision uncertainty.

Peer-reviewed publication

Methods in Systematic Reviews of Health Economic Evaluations in Submissions to Health Technology Assessment Agencies: How Systematic Are They, and Does This Matter?

YHEC authors: Chris Bartlett, Rachael McCool, Matthew Taylor
Publication date: October 2026
Journal: PharmacoEconomics

Abstract

Systematic reviews of health economic evaluations (SR-HEEs) are perceived as mandatory components of the health technology assessment (HTA) process in many jurisdictions. However, HTA agencies vary in how they prescribe reviews of HEEs should be conducted and the explicit purpose they serve. This article identifies the requirements of prominent HTA agencies, reports on the real-world conduct of SR-HEEs by health technology developers (HTDs), and explores their utility in the HTA process. International HTA guidelines were consulted, alongside a targeted review of SR-HEEs submitted to the National Institute for Health and Care Excellence (NICE) in 2024. While a systematic approach is a constant requirement to reviews of HEEs, it is defined inconsistently across agencies, with clinical and safety systematic reviews (SRs) receiving more rigid prescription. Consequently, SR-HEEs submitted to NICE demonstrated mixed methods. Despite these pragmatic deviations of SR-HEEs, External Assessment Groups (EAGs) raised no major concerns, and reimbursement decisions do not appear to be influenced. Our findings suggest a rigor gap between SR theory and practice, driven by the inherent heterogeneity of economic models, which renders quantitative pooling inappropriate. We submit that a more pragmatic approach to reviews of HEEs would be appropriate for HTA. To maximize utility and reduce resource waste, we propose a two-stage framework: early pragmatic “landscape mapping” to inform early model conceptualization, followed by a formal SR-HEE only when a specific useful research question is identified. This strategic realignment, possibly supported by emerging technologies, would enable HTA resources to be reallocated toward higher-value activities.

1 2 3 … 83